A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard of care (SOC) of LONSURF (trifluridine and tipiracil) plus bevacizumab in adult participants with c-Met over-expressed refractory metastatic colorectal cancer (mCRC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. Participants will then be randomized into 2 groups called treatment arms. One group will receive telisotuzumab adizutecan with bevacizumab in different doses. Another group will receive standard of care (SOC), trifluridine and tipiracil (LONSURF), with Bevacizumab. Up to approximately 700 adult participants with refractory mCRC, will be enrolled in the study in approximately 125 sites globally. In this Phase 3, one of two groups will receive doses of Intravenous (IV) telisotuzumab adizutecan + bevacizumab and other group will receive oral SOC of trifluridine/tipiracil (LONSURF)+ Intravenous (IV) bevacizumab. The study will run for a duration of approximately of 36 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent musi wyrazić świadomą zgodę na udział w badaniu.
- •Przewidywany czas życia pacjenta musi wynosić co najmniej 12 tygodni.
✗ Disqualifies
- •Pacjent nie mógł wcześniej przyjmować leków celowanych w c-Met.
- •Pacjent nie może mieć historii reakcji alergicznych na bewacizumab lub podobne substancje.
- •Pacjent nie może mieć historii nadużywania alkoholu lub substancji psychoaktywnych w ciągu ostatnich 6 miesięcy.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 30, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (9)
Astera Cancer Care /ID# 279532
East Brunswick, United States
Algemeen Ziekenhuis klina /ID# 279331
Brasschaat, Belgium
National Cancer Center Hospital East /ID# 279917
Kashiwa-shi, Japan
Dong-A University Medical Center /ID# 279610
Busan, South Korea
Gachon University Gil Medical Center /ID# 279592
Incheon, South Korea
Taipei Medical University Hospital /ID# 280607
Taipei, Taiwan
Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare /ID# 279708
New Taipei City, Taiwan
Tri-Service General Hospital - Neihu Branch /ID# 279768
Taipei, Taiwan
Taipei Municipal Wan Fang Hospital /ID# 280285
Taipei, Taiwan
Trial contact
ABBVIE CALL CENTER
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.